ArticleBJU international2026
Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the diagnostic performance of the Conformité Européenne [CE]-certified microRNA-371a-3p (miR371a) assay in patients undergoing inguinal exploration for small testicular masses of unknown histology in a real-world setting. PATIENTS AND
methodsBetween March 2023 and March 2024, 60 patients underwent inguinal exploration for testicular masses of unknown histology. For miR371a analysis, peripheral venous blood was obtained and sent to the Department of Molecular Pathology within 30 min. The extracted miRNA was reverse-transcribed into complementary DNA (cDNA) with miRNA-specific stem-loop primers, followed by a pre-amplification step. Using quantitative polymerase chain reaction, the miR371a is quantified. The median crossing points of the triplicates was calculated and converted into a relative quantification value.
resultsThe evaluation of the miR371a assay showed a true-positive result in 25 patients with seminoma. Eight patients with seminoma had false-negative results. In the non-seminoma group, six of seven (86%) patients had a true positive result. The false-negative finding derived from a non-seminomatous germ cell tumour (NSGCT) with predominant teratoma. The test was true-negative in 16 patients with sarcoma, diffuse large B-cell lymphoma, Leydig cell tumour, and Sertoli cell tumour. False-positive results were obtained in four patients. The results yield a sensitivity of 77.5%, a specificity of 80% and a positive predictive value of 88.6% and negative predictive value of 64% for the miR371a test in our cohort. In the seminoma cohort, the sensitivity of the serum tumour markers was 12%. In the NSGCT cohort, the sensitivity was 66%. DISCUSSION: In the absence of suitable markers, the miR371a assay shows promising results in the preoperative diagnosis of suspected localised small testicular tumour. Standardisation of pre-analytical handling and prospective multicentre validation are essential to define its optimal role in preoperative decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.